Literature DB >> 22095569

Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.

Jeremy D Keenan1, Berhan Ayele, Teshome Gebre, Jeanne Moncada, Nicole E Stoller, Zhaoxia Zhou, Travis C Porco, Charles E McCulloch, Bruce D Gaynor, Paul M Emerson, Julius Schachter, Thomas M Lietman.   

Abstract

Twelve trachoma-hyperendemic communities were treated with 3 annual mass azithromycin distributions. Children aged 0-9 years were monitored 1 year following the third treatment. An RNA-based test detected ocular chlamydial infection in more children than did a DNA-based test (6.9% vs 4.2%), and in a larger number of communities (8 vs 7).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22095569      PMCID： PMC3245728          DOI： 10.1093/cid/cir791

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Confirming positive results of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: all NAATs are not created equal.

Authors:  J Schachter; E W Hook; D H Martin; D Willis; P Fine; D Fuller; J Jordan; W M Janda; M Chernesky
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

2.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

3.  Trachoma and ocular Chlamydia trachomatis rates in children in trachoma-endemic communities enrolled for at least three years in the Tanzania National Trachoma Control Programme.

Authors:  H Mkocha; B Munoz; S West
Journal:  Tanzan J Health Res       Date:  2009-07

4.  Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.

Authors:  Teshome Gebre; Berhan Ayele; Mulat Zerihun; Asrat Genet; Nicole E Stoller; Zhaoxia Zhou; Jenafir I House; Sun N Yu; Kathryn J Ray; Paul M Emerson; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Bruce D Gaynor
Journal:  Lancet       Date:  2011-12-20       Impact factor: 79.321

5.  High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay.

Authors:  Max Chernesky; Dan Jang; Kathy Luinstra; Sylvia Chong; Marek Smieja; Wenjie Cai; Beth Hayhoe; Eder Portillo; Cindy Macritchie; Cheryl Main; Ruth Ewert
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

6.  Evaluation of three years of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma.

Authors:  Jeremiah Ngondi; Teshome Gebre; Estifanos B Shargie; Liknaw Adamu; Yeshewamebrat Ejigsemahu; Tesfaye Teferi; Mulat Zerihun; Berhan Ayele; Vicky Cevallos; Jonathan King; Paul M Emerson
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-01-28       Impact factor: 2.184

7.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?

Authors:  Mariko Bird; Chandler R Dawson; Julius S Schachter; Yinghui Miao; Ahmed Shama; Ahmed Osman; Ahmad Bassem; Thomas M Lietman
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

8.  Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.

Authors:  Jon L Yang; Kevin C Hong; Julius Schachter; Jeanne Moncada; Takele Lekew; Jenafir I House; Zhaoxia Zhou; Melissa D Neuwelt; Tina Rutar; Colleen Halfpenny; Neelima Shah; John P Whitcher; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

9.  Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.

Authors:  Jesse B Biebesheimer; Jenafir House; Kevin Cyrus Hong; Takele Lakew; Wondu Alemayehu; Zhaoxia Zhou; Jeanne Moncada; Andrew Rogér; Jeremy Keenan; Bruce D Gaynor; Julius Schachter; Thomas M Lietman
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

10.  Reduction and return of infectious trachoma in severely affected communities in Ethiopia.

Authors:  Takele Lakew; Jenafir House; Kevin C Hong; Elizabeth Yi; Wondu Alemayehu; Muluken Melese; Zhaoxia Zhou; Kathryn Ray; Stephanie Chin; Emmanuel Romero; Jeremy Keenan; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  PLoS Negl Trop Dis       Date:  2009-02-03
  10 in total
  8 in total

Review 1.  Chlamydial infection during trachoma monitoring: are the most difficult-to-reach children more likely to be infected?

Authors:  Jeremy D Keenan; J Moncada; T Gebre; B Ayele; M C Chen; S N Yu; P M Emerson; N E Stoller; C E McCulloch; B D Gaynor; J Schachter
Journal:  Trop Med Int Health       Date:  2011-11-28       Impact factor: 2.622

2.  Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Authors:  Jeremy D Keenan; Craig W See; Jeanne Moncada; Berhan Ayele; Teshome Gebre; Nicole E Stoller; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

Review 3.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

4.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

Review 5.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

Review 6.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

7.  The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.

Authors:  Fengchen Liu; Travis C Porco; Harran A Mkocha; Beatriz Muñoz; Kathryn J Ray; Robin L Bailey; Thomas M Lietman; Sheila K West
Journal:  Epidemics       Date:  2014-01-08       Impact factor: 4.396

8.  Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.

Authors:  Jonathan D King; Tesfaye Teferi; Elizabeth A Cromwell; Mulat Zerihun; Jeremiah M Ngondi; Mesele Damte; Frew Ayalew; Zerihun Tadesse; Teshome Gebre; Ayelign Mulualem; Alemu Karie; Berhanu Melak; Mitku Adugna; Demelash Gessesse; Abebe Worku; Tekola Endashaw; Fisseha Admassu Ayele; Nicole E Stoller; Mary Rose A King; Aryc W Mosher; Tesfaye Gebregzabher; Geremew Haileysus; Peter Odermatt; Jürg Utzinger; Paul M Emerson
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.